NASDAQ:TLSA Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $0.57 +0.00 (+0.72%) As of 03:19 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Tiziana Life Sciences Stock (NASDAQ:TLSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tiziana Life Sciences alerts:Sign Up Key Stats Today's Range$0.55▼$0.6150-Day Range$0.57▼$1.1952-Week Range$0.55▼$1.90Volume474,631 shsAverage Volume401,590 shsMarket Capitalization$73.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Tiziana Life Sciences is a biotechnology company developing treatments for inflammatory and neurodegenerative diseases. Its development work has focused on foralumab, a fully human monoclonal antibody that targets CD3, a protein found on T cells involved in the immune response. The company is investigating an intranasal formulation of foralumab for conditions including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. These uses remain investigational, and foralumab is not an approved treatment. Tiziana has concentrated its research and development on advancing this immune-modulating therapy through clinical studies.AI Generated. May Contain Errors. Read More Tiziana Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreTLSA MarketRank™: 0.48402068691 of 5 starsTiziana Life Sciences scored higher than 10% of companies evaluated by MarketBeat, and ranked 852nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingTiziana Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageTiziana Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Tiziana Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.82% of the float of Tiziana Life Sciences has been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 6.98.Change versus previous monthShort interest in Tiziana Life Sciences has recently increased by 4.71%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTiziana Life Sciences does not currently pay a dividend.Dividend GrowthTiziana Life Sciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News SentimentTiziana Life Sciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Tiziana Life Sciences this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTiziana Life Sciences has minimal institutional ownership at this time.Read more about Tiziana Life Sciences' insider trading history. Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSA Stock News HeadlinesTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in LondonNovember 12, 2026 | uk.finance.yahoo.comTiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in LondonNovember 12, 2026 | finanznachrichten.deA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.November 16 at 1:00 AM | The Tomorrow Investor (Ad)BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)November 11, 2026 | theglobeandmail.comTiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis TranscriptNovember 9, 2026 | seekingalpha.comTiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients ...November 9, 2026 | markets.businessinsider.comTiziana’s nasal foralumab reduces microglial activation in progressive MS trialNovember 9, 2026 | finance.yahoo.comTiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal ForalumabNovember 9, 2026 | globenewswire.comSee More Headlines TLSA Stock Analysis - Frequently Asked Questions How have TLSA shares performed this year? Tiziana Life Sciences' stock was trading at $1.49 at the start of the year. Since then, TLSA shares have decreased by 61.7% and is now trading at $0.57. When did Tiziana Life Sciences IPO? Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. Who are Tiziana Life Sciences' major shareholders? Tiziana Life Sciences' top institutional investors include Marshall Wace LLP (0.93%), Mid American Wealth Advisory Group Inc. (0.35%) and China Universal Asset Management Co. Ltd.. View institutional ownership trends. How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Tesla (TSLA), NVIDIA (NVDA), NIO (NIO), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA). Company Calendar Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TLSA's financial health is in the Red zone, according to TradeSmith. TLSA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TLSA CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees10Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares127,260,000Free Float76,584,000Market Cap$73.94 million OptionableOptionable Beta0.49 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TLSA) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.